



PRESS RELEASE

MolMed at the “Cell & Gene Meeting on the Mediterranean” conference on the opportunities of price and reimbursement in the advanced therapies field.

Milan (Italy), April 25th, 2019 - MolMed S.p.A. (MLMD.MI), a biotechnology company focused on research, development, production and clinical validation of gene and cell therapies for the treatment of cancer and rare diseases joined the Cell & Gene Meeting on the Mediterranean Conference, which has just ended in Barcelona.

The event, organized every year by the Alliance of Regenerative Medicine (ARM), also this year hosted the major international players in the Cell & Gene field, to discuss a wide range of topics, from technological innovation to commercialization, market access, regulatory issues and finances opportunities, through a series of panels led by experts, one-to-one meetings and exclusive networking opportunities.

Today, Luca Alberici MolMed's Chief Business Officer, spoke at the Panel *“The pricing and reimbursement landscape: opportunities and challenges”*.

“Cell & Gene Meeting on the Mediterranean is one of the most awaited events by those like MolMed develops and manufactures cell and gene therapies, field where our experience and excellence is widely recognized.” Commented Luca Alberici MolMed's Chief Business Officer *“This year MolMed, being one of the first companies that brought to the European market an advanced therapy, had the chance to contribute to the discussion on a key topic for the development of this industry: the policies of price and reimbursement. We believe that important opportunities will arise in the short and long period in our field, and that is therefore important to highlight the fundamental role covered by companies not only in the research, development and manufacturing, but in the development of innovative therapies market access and price negotiation processes as well”*.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed's product portfolio includes proprietary anti-tumor therapies in both clinical and preclinical development: Zalmoxis® (TK) is a cell therapy based on donor T cells genetically engineered to enable bone marrow transplants from partially compatible donors for patients with high-risk hematological malignancies, eliminating post-transplant immunosuppression prophylaxis and inducing a rapid immune reconstitution. Zalmoxis®, that received orphan drug designation and is currently in Phase III in a high-risk population of acute leukemia patients, but has already obtained a Conditional Marketing Authorization by the European Commission in the second half of 2016 as well as reimbursement conditions in Italy and in Germany at the beginning of 2018. Still focusing on this cell & gene technology, the Company is developing a new therapeutic platform based on Chimeric Antigen Receptor (CAR), both autologous and allogeneic; the most advanced product, CAR-T CD44v6, which on March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase; the



PRESS RELEASE

product is potentially effective also in several epithelial solid tumors. With regards to allogeneic CARs, MolMed is developing a pipeline based on NK (Natural Killer) cells, following a research agreement signed in 2018 with Glycostem. MolMed is also the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies for its proprietary products (Zalmoxis®) as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. In the field of innovative oncological therapies MolMed pipeline also includes NGR-hTFN, a therapeutic agent for the treatment of solid tumors. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso.

For further information:

Ilaria Candotti

Investor Relations & Communication Manager

MolMed S.p.A.

+39 02 21277.205

+39 02 21277.325

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it